AdipoGen Life Sciences

anti-Vaspin (human), mAb (VP63)

CHF 310.00
In stock
AG-20A-0045-C05050 µgCHF 310.00
AG-20A-0045-C100100 µgCHF 430.00
More Information
Product Details
Synonyms Visceral Adipose Tissue-derived Serine Protease Inhibitor; Serpin A12; OL-64
Product Type Monoclonal Antibody
Properties
Clone VP63
Isotype Mouse IgG1κ
Immunogen/Antigen Recombinant human vaspin.
Application

ELISA: (direct or indirect: 1:2'000-1:5'000)
Immunohistochemistry: frozen sections (1:100)
Western blot: (1:2'000-1:5'000 using ECL. Suggested blocking and dilution buffer is PBST with 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at rooom temperature).
Optimal conditions should be determined individually for each application.

Crossreactivity Human
Specificity

Recognizes human vaspin. Detects a band of ~48kDa by Western blot.

Purity Detail Protein G-affinity purified.
Concentration 1mg/ml
Formulation Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Isotype Negative Control

Mouse IgG1 Isotype Control

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Vaspin (Visceral adipose tissue-derived serpin; Serpin A12), a serine protease inhibitor (serpin), is an insulin-sensitizing adipocytokine that has been isolated from both visceral and subcutaneous white adipose tissue. Based on recent findings, vaspin is suggested to regulate immune responses and inflammation and was found to be correlated with various metabolic parameters. Vaspin may represent a novel biomarker for obesity and impaired insulin sensitivity and might serve as a new therapeutic target of metabolic syndrome.

Product References
  1. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects: N. Klöting, et al.; Diabetologia 54, 1819 (2011)
  2. Untersuchungen zur Rolle von Vaspin in der Psoriasis: K. Rall; Diss. Universität Leipzig (2012) (IHC protocol)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.